Dr. Getts is the CEO and co-founder of Myeloid Therapeutics. Prior to Myeloid, he was the VP of Research at TCR2 (NASDAQ, TCRR) and a member of the leadership team that successfully guided the company through a series B ($120M) financing and an IPO (~$80M). Dr. Getts’s primary duties were to lead the company’s target discovery, preclinical, and translational research programs. These efforts resulted in numerous patent applications, a robust pipeline, and a successfully filed IND. Before TCR2, Dr. Getts was the primary inventor, founder, and CSO of Cour Pharmaceuticals Development Company — a nanotechnology platform company focused on autoimmunity and inflammation. As a member of the company’s leadership team, he assisted in negotiating several pharmaceutical company collaborations and licenses, including Takeda, which ultimately licensed TIMP-GLIA for $420M. Dr. Getts has received numerous honors and awards, over 10 issued patents, and many more pending patent applications. He is widely published, including over 45 peer-reviewed publications with seminal publications in Nature Biotechnology, Science Translational Medicine, and Nature Communications. Dr. Getts completed his postdoctoral training at Northwestern University in Stephen D. Miller’s laboratory. He holds a PhD in Medicine from the University of Sydney and an MBA from Western Michigan University.